Atossa Genetics Announces Warrant Exercises
June 30, 2017 10:36 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jun 30, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer...
Atossa Genetics Receives Positive Safety Committee Assessment of First Cohort Receiving Oral Formulation of Endoxifen in Phase 1 Dose Escalation Study
June 26, 2017 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jun 26, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer...
Atossa Genetics to Present at the LD Micro Invitational on June 6, 2017
June 01, 2017 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jun 1, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
Atossa Genetics Completes Enrollment in Topical Arm of Endoxifen Phase 1 Study
May 19, 2017 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 19, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
Atossa Genetics Announces First Quarter 2017 Financial Results and Provides Company Update
May 11, 2017 17:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 11, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced First Quarter ended March 31, 2017 financial results and provided an update on recent company...
Atossa Genetics Receives Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study
May 10, 2017 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 10, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company, today announced that it has received the second positive interim review on...
Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study
May 09, 2017 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 9, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study
April 20, 2017 08:15 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Apr 20, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company, today announced that it has received a positive interim review on its...
Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study
April 04, 2017 08:15 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Apr 4, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it has fully enrolled the first of six cohorts (eight participants per cohort) in its Phase 1...
Atossa Genetics Closes Public Offering
April 03, 2017 16:05 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Apr 3, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced the closing of its previously announced underwritten public offering with gross proceeds to Atossa of...